参考文献：1.Borst J, Busselaar J, Bosma DMT, Ossendorp F. Mechanism of action of PD-1 receptor/ligand targeted cancer immunotherapy. Eur J Immunol. 2021 Aug;51(8):1911-1920.2.Zhiyong Li, Zhuowei Liu, et al.Preliminary results from a phase II study of tislelizumab combined with radi...
Mechanism of action of PD-1 receptor/ligand targeted cancer immunotherapy. Eur J Immunol. 2021 Aug;51(8):1911-1920. 2.Zhiyong Li, Zhuowei Liu, et al.Preliminary results from a phase II study of tislelizumab combined with radiotherapy as bladder-preserving treatment for patients with high-...
However, anti-PD-L1 antibody, atezolizumab, provide clinical benefit even in the subgroup of cancer patients where PD-L1 is low or undetectable on tumor cells and tumor-infiltrating immune cells (TC0/IC0). In this study, we investigated the mechanism of action by which PD-L1-negative tumors...
2. Ni Zhang, et al. Programmed cell death-1/programmed cell death ligand-1 checkpoint inhibitors: differences in mechanism of action. Immunotherapy. 2019
we develop a multi-paratopic VEGF decoy receptor, dubbed “Ate-Grab,” to sequester PlGF/VEGF within the TME. The antitumor and anti-fibrotic effects of Ate-Grab are explored, in addition to its mechanism of action. These findings provide a mechanistic basis for developing efficient therapeutic ...
PhD, CEO and CSO of Molecular Templates. “The PD-1/PD-L1 axis is central to many tumors and targeting that axis with a new mechanism of action has an opportunity to provide meaningful benefit to patients. We look forward to provid...
RCC patients [77]. The dissimilarity between the outcomes might be correlated to the action mechanism of vaccines because AGS-003 is made up of a reinforcement of APC, which enable T cells stimulation, and IMA901 is made up of small fragments of peptides expressed in cancer cells. Lacking ...
LAG3’s Enigmatic Mechanism of Action. Front Immunol. 11:2021. Goding SR, Wilson KA, Xie Y, Harris KM, Baxi A, Akpinarli A, Fulton A, Tamada K, Strome SE. Antony: restoring Immune function of Tumor-Specific CD4 < SUP>+ T cells during recurrence of Melanoma. J Immunol. 2013...
eventually revealed that it also operates as a brake, but with a different mechanism of action. ...
Programmed cell death-1/programmed cell death ligand-1 checkpoint inhibitors: differences in mechanism of action. Immunotherapy. 2019 发布于 2024-05-07 13:24・IP 属地北京 1 网络大 V 司马南偷税被罚超 900 万元,如何看待此事?哪些信息值得关注? 4808 万热度 2 湖北大学通报女生失联事件,女生尸体在...